Table 3 Univariate and multivariate logistic regression analysis for residual disease in the discovery and validation cohorts
|  | Discovery set ( n = 30) | Validation set ( n = 154) | ||||
|---|---|---|---|---|---|---|
OR | 95% CI | P value | OR | 95% CI | P value | |
Univariate logistic regression analysis | ||||||
 Age (years) (≥ 60 vs. < 60) | 0.375 | 0.073 ~ 1.920 | 0.229 | 0.795 | 0.390 ~ 1.622 | 0.529 |
 Stage (IV vs. III) | 5.091 | 0.496 ~ 52.287 | 0.130 | 10.601 | 3.537 ~ 31.775 |  < 0.0001 |
 Lymph node metastasis (positive vs. negative) | 1.375 | 0.286 ~ 6.603 | 0.690 | 2.561 | 1.275 ~ 5.144 | 0.0075 |
 P53 mutation (Positive vs. Negative) | 0.762 | 0.179 ~ 3.241 | 0.712 | 1.167 | 0.519 ~ 2.623 | 0.710 |
 Serum CA-125 (≥ 600 vs. < 600 U/ml) | 5.688 | 0.939 ~ 34.458 | 0.042 | 4.767 | 2.261 ~ 10.054 |  < 0.0001 |
 4-miRNA panel (High vs. Low risk) | 91 | 7.348 ~ 1126.947 |  < 0.0001 | 29.721 | 12.299 ~ 71.826 |  < 0.0001 |
Multivariate logistic regression analysis | ||||||
 Age (years) (≥ 60 vs. < 60) | 1.156 | 0.862 ~ 1.551 | 0.342 | 0.963 | 0.844 ~ 1.100 | 0.581 |
 Stage (IV vs. III) | 0.863 | 0.597 ~ 1.247 | 0.441 | 1.169 | 1.005 ~ 1.359 | 0.045 |
 Lymph node metastasis (Positive vs. Negative) | 1.048 | 0.787 ~ 1.395 | 0.753 | 1.142 | 1.005 ~ 1.297 | 0.044 |
 P53 mutation (Positive vs. Negative) | 0.952 | 0.740 ~ 1.226 | 0.709 | 1.030 | 0.899 ~ 1.180 | 0.672 |
 Serum CA-125 (≥ 600 vs. < 600 U/ml) | 1.047 | 0.785 ~ 1.395 | 0.759 | 1.249 | 1.096 ~ 1.424 | 0.001 |
 4-miRNA panel (High vs. low risk) | 2.415 | 1.779 ~ 3.279 |  < 0.0001 | 1.866 | 1.649 ~ 2.110 |  < 0.0001 |